Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

HCM Defined, HCM Revealed

Premiere Date: Friday, July 16, 2021

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. ABIM (MOC)
4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, July 16, 2022
Note: Credit Is No Longer Available

Faculty

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC (Moderator) Executive Director of Interventional Cardiovascular Programs Brigham and Women's Hospital Heart & Vascular Center Professor of Medicine, Harvard Medical School Boston, MA

Statement of Need

Hypertrophic cardiomyopathy (HCM) is when the left ventricle is hypertrophied in the absence of another cardiac or systemic disease that could produce a similar magnitude of hypertrophy. HCM is the most common genetic heart disease with vast clinical and phenotypic heterogeneity with a worldwide prevalence of 1:200. It is the most common cause of sudden death in the young, and many patients are free of clinically significant features until triggered by a cardiac event. Due to under-recognition of disease and under-referral for specialized HCM treatment, women and underserved minorities have been disproportionately affected.

The first installment in this CME Outfitters Snack series on HCM focuses on recognizing the array of presenting symptoms of HCM in order to facilitate an accurate diagnosis and referral, including the utilization of guideline recommendations for diagnostic assessment and risk stratification.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate appropriate patients for HCM using evidence-based screening and diagnostic strategies.

Financial Support

Supported by an educational grant from Bristol Myers Squibb

Target Audience

Cardiologists, interventional cardiologists, electrophysiologists, internists, primary care clinicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.25 contact hours (0.025 CEUs) Universal Activity Number:
Enduring: JA0007185-0000-21-147-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of 0.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit^TM from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bhatt reports that he is a consultant for Abbott; Afimmune; AmarinCorporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals: Forest Laboratories; Fractyl Laboratories, Inc.; HLS Therapeutics, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Janssen Pharmaceuticals, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; MyoKardia; Novo Nordisk; OWKIN, INC.; Pfizer Inc.; PhaseBio Pharmaceuticals, Inc.;PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.

Dr. Maron reports that he is a steering committee member for Cytokinetics, Inc. He is a consultant for Imbria Pharmaceuticals.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).